Already long, will continue to add heavy into that area. I would suggest checking out @Pharmdca analysis of the company over the past at-least few months.
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.